Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

サイズ 価格(税別)  
JPY 25730.00
JPY 14940.00
JPY 28220.00
JPY 53120.00
JPY 94620.00

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MYfGeY5kfGmxbjDBd5NigQ>? MWiwMlXDqM7:TR?= MUSyOEBp M2Hk[ZdifGW{ NXLuT41udW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? NF3NRYIzPTF{M{C4Ni=>
Eca109 NUXWR5l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK3RpIxNjVxMj61M|Uh|ryP MY[yOE81QC95MjDo MWn3ZZRmeg>? NGm3d5RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M{jh[|I2OTJ|MEiy
Eca109 NFfWNZZHfW6ldHnvckBCe3OjeR?= MYiwMlXDqM7:TR?= M1;zU|YwOTJxMkSgbC=> NHLQdnZ4[XSnch?= NHi0bYpqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg MmfPNlUyOjNyOEK=
Eca109 NXS4bodMTnWwY4Tpc44hSXO|YYm= NIDmW4UxNjYEoN88US=> MoLONlQhcA>? M{LqbJdifGW{ NV:5R|J2cW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M3zOOlI2OTJ|MEiy
Eca109 M3\Od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ISFAvPcLizszN NEHFfWczPCCq MUn3ZZRmeg>? MWTpcoR2[2W|IFeyM20h[XK{ZYP0JIlvKHSqZTDj[YxtKGO7Y3zl NU\4OYpnOjVzMkOwPFI>
Eca109 NHjNcplHfW6ldHnvckBCe3OjeR?= NXLsfI9xOC53L{Gg{txO MnfnNlQhcA>? MXT3ZZRmeg>? NWDad2RR\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= M2rVSVI2OTJ|MEiy
SW1116  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfhbpJNOC53L{GvNk82KM7:TR?= MY[0PEBp NF3HOmZFVVOR MYHlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NXXjT3ZROjR6N{SyPFY>
LOVO Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7udGUxNjVxMT:yM|Uh|ryP NUmwWnpzPDhiaB?= NHjE[ItFVVOR NF3WT5NmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v MkLGNlQ5PzR{OE[=
SW1116  NEfHVnpHfW6ldHnvckBCe3OjeR?= M17HWlExKM7:TR?= M1n3NlQ5KGh? NHLQXZpFVVOR MVrpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> Mom0NlQ5PzR{OE[=
LOVO NGXjWIhHfW6ldHnvckBCe3OjeR?= MX[xNEDPxE1? MXK0PEBp NIHuclJFVVOR NGTCWW1qdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? NV3ZcYFiOjR6N{SyPFY>
SW1116  NYXKOZhjSXCxcITvd4l{KEG|c3H5 NYXPbWZkOTBizszN NGG1SlA1QCCq NGHYXHFFVVOR MYLlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NHLmVYozPDh5NEK4Oi=>
LOVO MXXBdI9xfG:|aYOgRZN{[Xl? MXqxNEDPxE1? M1TtTVQ5KGh? MmKwSG1UVw>? MVHlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= M3LHO|I1QDd2Mki2
RPMI-8226 NGfjbIZCeG:ydH;zbZMhSXO|YYm= M3vFfFEwOiEQvF2= M1SzSVQ5Nzd{L{m2JIg> M4fFXWROW09? NWO2R|NNcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MoLPNlQ5OzNzMEi=
OPM-2  MVzBdI9xfG:|aYOgRZN{[Xl? MnWyNU8zKM7:TR?= MVq3Nk86Pi9zMkCgbC=> NXPsb4t6TE2VTx?= NEW5UXZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXjPVZZQOjR6M{OxNFg>
JJN3  MYfBdI9xfG:|aYOgRZN{[Xl? MlPQNE42NzFizszN M1PTWFI1NzR6IHi= MVfEUXNQ NI\ycHpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlrLNlQ5OzNzMEi=
NCI-H929  MULBdI9xfG:|aYOgRZN{[Xl? NXPzeXpDOS9{IN88US=> MVG3Nk86Pi9zMkCgbC=> M{K4bGROW09? M17PU4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MoDxNlQ5OzNzMEi=
RPMI-8226 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojpNU8zKM7:TR?= MkHFNlQwPDhxN{KgbC=> NGLPWZdFVVOR M1\WZ4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NED6SYEzPDh|M{GwPC=>
OPM-2  NHHMemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXWSFUyNzJizszN NWrPVmxNOjRxNEivO|IhcA>? MYTEUXNQ NYTXeW9D[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NHX0dGkzPDh|M{GwPC=>
JJN3  Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYiwMlUwOSEQvF2= NE[wN5IzPC92OD:3NkBp NWTqOZA3TE2VTx?= NHX5PJJi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NFvHbpMzPDh|M{GwPC=>
NCI-H929  M1XNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTiVVNqOS9{IN88US=> NX\GNmVOOjRxNEivO|IhcA>? NWXBXGk4TE2VTx?= NUj1dFFE[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NW[xTocyOjR6M{OxNFg>
HeLa MWjLbY5ie2ViQYPzZZk> NFuxO|NMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy MVeyOFc5ODB7OB?=
HeLa MYPLbY5ie2ViQYPzZZk> MmLxT4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy NEn2S|UzPDd6MEC5PC=>
HeLa NHPDcWhMcW6jc3WgRZN{[Xl? NGTqR4pMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy NFHlWGwzPDd6MEC5PC=>
HeLa MkTvT4lv[XOnIFHzd4F6 MmCzT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> NW[2cphzOjR5OECwPVg>
NB4 MnH0SpVv[3Srb36gRZN{[Xl? NHfW[pEzNjVxNT:3MlUwOTBizszN M2r5OFI1KGh? M3jqNmROW09? MmfHbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> MYGyOFQ5PDh5MB?=
CD4+ CD25− T  M2SyZ2Z2dmO2aX;uJGF{e2G7 MnKyNU82KM7:TR?= NX23elQxemWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w Ml\hNlQ1PzZ|NkC=
BV-173 NHGzTGRCeG:ydH;zbZMhSXO|YYm= NYHKWWV4OC5{NT:wMlUwOC55NT:xJO69VQ>? MXG0PE84Oi97NjDo NEDXdYPDqFCEUx?= M4r5folv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MkLtNlQ1OjN4MUO=
ML-1 M13Mc2Fxd3C2b4Ppd{BCe3OjeR?= MWqwMlI2NzBwNT:wMlc2NzFizszN MXi0PE84Oi97NjDo NHq0dlXDqFCEUx?= NHy3SnhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NXfNT41IOjR2MkO2NVM>
HL-60 MXjBdI9xfG:|aYOgRZN{[Xl? M3Hk[VAvOjVxMD61M|AvPzVxMTFOwG0> NEO0cWI1QC95Mj:5OkBp NXHXfFRnyqCSQmO= NF7SOZBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NYHIXGxpOjR2MkO2NVM>
KG-1a Mm[1RZBweHSxc3nzJGF{e2G7 MnjlNE4zPS9yLkWvNE44PS9zIN88US=> MnfJOFgwPzJxOU[gbC=> M4G5SeKhWEKV MofybY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy Moj1NlQ1OjN4MUO=
BV-173 NGTIcXpHfW6ldHnvckBCe3OjeR?= MYSyOVAwPTBybl2= MlzCOFghcA>? M4P5cuKhWEKV M33Zdolv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MYqyOFQzOzZzMx?=
CEM NVLnfId3TnWwY4Tpc44hSXO|YYm= M3qx[|I2OC93MEDuUS=> MojuOFghcA>? MVdCpHBDWw>? MYTpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MWmyOFQzOzZzMx?=
HL-60 MYTGeY5kfGmxbjDBd5NigQ>? NIHFcI0zPTBxNUCwcm0> MXi0PEBp NESzepfDqFCEUx?= MWHpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NFvCPIgzPDR{M{[xNy=>
ML-1 NYTFV4RITnWwY4Tpc44hSXO|YYm= Mmi2NlUxNzVyMH7N NVvKSmI2PDhiaB?= NIXPb5jDqFCEUx?= NE\4dFVqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NX7lTXNQOjR2MkO2NVM>
DLD-1 NYH0SVlQTnWwY4Tpc44hSXO|YYm= MlvoNlUxNzVyMH7N MVS0PEBp MV5CpHBDWw>? MYXkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MnfQNlQ1OjN4MUO=
HCT-116 NGTuVHVHfW6ldHnvckBCe3OjeR?= MVGyOVAwPTBybl2= NXT0XFRDPDhiaB?= MUZCpHBDWw>? M1fsd4RwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MlXWNlQ1OjN4MUO=
U937-A/E-9/14/18  M2DZNGFxd3C2b4Ppd{BCe3OjeR?= MlrrNE4xOS9yLkGvNU8yOCEQvF2= MWe0PEBp MVfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnTUNlQ{ODB2NU[=
HT29 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[3NkBp NV\ZUox4UUN3ME2xOFAxyrFzN{mg{txO NWH5eYxKOjRzN{KwOlE>
SW48 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLrVnNNPzJiaB?= MYLJR|UxRTF3LkNCtVYvOiEQvF2= MnzQNlQyPzJyNkG=
HCT116 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfD[VE4OiCq MULJR|UxRTFwN9MxNE41KM7:TR?= NV\w[mZYOjRzN{KwOlE>
HepG2 M4DsVmZ2dmO2aX;uJGF{e2G7 M{LWWVAvPS9zIN88US=> MlnUNlQhcA>? NELFS3pFVVOR MWr1dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? NGfydWgzPDF2Nki3OC=>
LS174T MX3GeY5kfGmxbjDBd5NigQ>? MlWwNE42NzFizszN NIjiOIszPCCq MWrEUXNQ M1f4Xoxm[WRidH:gZY4hcW6lcnXhd4Uhd2ZiT1PUUlIhdGW4ZXzz M4q0RlI1OTR4OEe0
HepG2 M4nNW2Fxd3C2b4Ppd{BCe3OjeR?= M1\yeFEwOTBxMUCwJO69VQ>? NF7WRpE4KGR? MV3EUXNQ MYrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYX5[XVyOjRzNE[4O|Q>
LS174T M{XHNGFxd3C2b4Ppd{BCe3OjeR?= NY\VWpFCOS9zMD:xNFAh|ryP NFTkfm04KGR? MXfEUXNQ NX;HeopxcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIeweHYzPDF2Nki3OC=>
QBC-939 NYfYdItSSXCxcITvd4l{KEG|c3H5 NVfGSm9mOS9zMD:xNFAh|ryP NFjvPI44KGR? NFzKcGRFVVOR NHuxNnlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MV6yOFE1Pjh5NB?=
U251 NFTBSHRCeG:ydH;zbZMhSXO|YYm= NFPoOXoyNzFyL{GwNEDPxE1? MlHMO{Bl MWTEUXNQ NUHHemxJcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWOyOFE1Pjh5NB?=
HL-60 NYKwdJpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rL[VEh|ryP NGPnW441QCCq MojqbY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? MWiyOFAxODN{NB?=
MDA‑MB‑453 M1TxcmZ2dmO2aX;uJGF{e2G7 MWmwMlIwOSEQvF2= NUnjcHFjPzJiaB?= NI\wSo9k[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MV[yN|g1PDJ{OB?=
HCC1569 MmjhSpVv[3Srb36gRZN{[Xl? M4XNeFAvOi9zIN88US=> MXe3NkBp NWn2R5Jo[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MVeyN|g1PDJ{OB?=
BT‑474 NEDKOWZHfW6ldHnvckBCe3OjeR?= NVfiSpQ4OC5{L{Gg{txO NWiyWYpFPzJiaB?= MmPOZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg M1S5VVI{QDR2MkK4
AGS NVTqUlEySXCxcITvd4l{KEG|c3H5 M2\RVlUwOTBxMkCvOVAh|ryP M{TDfVQ5yqCqwrC= NETWO3RFVVOR NFPHNGtqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NX:wXYxCOjN3OEK3PFQ>
A549 M3raZ2Fxd3C2b4Ppd{BCe3OjeR?= MUW1M|ExNzJyL{WwJO69VQ>? NYTM[GJqPDkEoHlCpC=> MVPEUXNQ NV2zTWxjcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? MnfVNlM2QDJ5OES=
AGS  MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[2PFUwOTBxMkCvOVAh|ryP M3O5cVQ5yqCqwrC= MXHEUXNQ M1PMO4lv\HWlZYOgS|IwVSCyaHHz[UBienKnc4VCpC=> MYqyN|U5Ojd6NB?=
Kasumi-1 NIT4[ZZCeG:ydH;zbZMhSXO|YYm= Mlv3NE42KM7:TR?= MXW0POKhcMLi MmPo[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NGq4d|UzOzR7M{O0PC=>
OCI-AML3 MlXSRZBweHSxc3nzJGF{e2G7 MkjENk42KM7:TR?= M{LY[VQ5yqCqwrC= MVrk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NXrQTHZCOjN2OUOzOFg>
MV4-11 NHro[5pCeG:ydH;zbZMhSXO|YYm= M1\iN|IvPSEQvF2= MXe0POKhcMLi NF;MS5Vl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NXTM[4IyOjN2OUOzOFg>
NK  Mo\uR5l1d3SxeHn0fUBCe3OjeR?= MlHRNE4xOi1{MDFOwG0> MV61JIQ> NHWycmxl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n NV3oZ286OjN|MkiwPFg>
NK  MkXtRZBweHSxc3nzJGF{e2G7 NVnxfGt7OC5yMj2yNEDPxE1? MYi1JIQ> NXm5TVlq\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm MoXMNlM{OjhyOEi=
NK  M3jPO2Z2dmO2aX;uJGF{e2G7 NV\VOpI4OC5yMT2yNEDPxE1? MoqzOUBl NYfQdmxi[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? M4XL[VI{OzJ6MEi4
MOLT4/DNR MnrESpVv[3Srb36gRZN{[Xl? NWX4VJRIPSEQvF2= MVW0JIQ> MlPGdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NVvZ[VhCOjNyNkC1O|A>
Jurkat/DOX MnzWSpVv[3Srb36gRZN{[Xl? NWPGV2M{PSEQvF2= MWO0JIQ> MUXy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> M{LJPVI{ODZyNUew
MOLT4/DNR M1\nfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPTOnY2KM7:TR?= NVX6OGJDPCCm Ml3qdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NFn1fHEzOzB4MEW3NC=>
Jurkat/DOX MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjvVVVDPSEQvF2= MYW0JIQ> M1;S[JJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= MV2yN|A3ODV5MB?=
ccRCC  M1rYN2Fxd3C2b4Ppd{BCe3OjeR?= NGq4S2IxNjBzLUGw{txO Ml7WO|IhcA>? NFKxelNFVVOR M4\sWIhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? MmW2NlI5OjZ2Nke=
TNBC  NGLtS5NCeG:ydH;zbZMhSXO|YYm= MVKwMlAyNTFyzszN MXm3NkBp NYnn[XNjTE2VTx?= NFTnellp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w NUjNPIRNOjJ6Mk[0Olc>
A498 Ml3YRZBweHSxc3nzJGF{e2G7 Mn64NE4xOS1zMN88US=> NYXaZmdOPzJiaB?= NUnZRZh6TE2VTx?= MmH1bY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M3\2[|IzQDJ4NE[3
KIJ265T MlzLRZBweHSxc3nzJGF{e2G7 MlTENE4xOS1zMN88US=> NX;0VFVZPzJiaB?= NX\acmN5TE2VTx?= NI\DS|hqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MVyyNlgzPjR4Nx?=
MDA-231 NGnk[lBCeG:ydH;zbZMhSXO|YYm= NYfmPFVCOC5yMT2xNO69VQ>? NFXMWoc4OiCq NHLzXXhFVVOR NECwd4JqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MWKyNlgzPjR4Nx?=
BT-20 MV\BdI9xfG:|aYOgRZN{[Xl? M17melAvODFvMUFOwG0> NHjL[ok4OiCq NETzSZFFVVOR MlLYbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MknINlI5OjZ2Nke=
U937 NWTPZYZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P5XlUuOjBizszN M1u1clI1NzR6L{eyJIg> Ml76bY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M3rVbFIzPzZ5MEKx
HL60 M2DCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHqZ2NUPS1{MDFOwG0> MXWyOE81QC95MjDo M4jJcolv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MV:yNlc3PzB{MR?=
U937 NFrEVY1CeG:ydH;zbZMhSXO|YYm= MXKxOUDPxE1? M3\R[VI1NzR6L{eyJIg> M4raeolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M{ntVFIzPzZ5MEKx
HL60 NXvLeWh7SXCxcITvd4l{KEG|c3H5 MoL3NVUh|ryP M4rzclI1NzR6L{eyJIg> NV\HR5BicW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M1KyOVIzPzZ5MEKx
LS411N  NUTHe2hjSXCxcITvd4l{KEG|c3H5 NFTKVFUxNjVizszN M2L6W|czKGh? MX;pcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? NUfhfFRCOjJ2NkG2PVU>
MDA-MB-231 NHrFPI5CeG:ydH;zbZMhSXO|YYm= MnnQNVAh|ryP NILPZ5Q1QCCq MUfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWmyNVg5PzZ7Nx?=
MCF-7  MWHBdI9xfG:|aYOgRZN{[Xl? MXGxNEDPxE1? NEO3SXU1QCCq M3v5WJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXX3clJxOjF6OEe2PVc>
A375 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOwMlUh|ryP NH\XV2oyNzVxODDk Mk\ybY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M2HRUVIyPzl4NkKy
SKMEL1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTP[5AxNjVizszN NG\POHgyNzVxODDk MmPMbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? Mn7XNlE4QTZ4MkK=
SKMEL3 NVvPXWtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP6OWVJOC53IN88US=> M1LFVFEwPS96IHS= NUW5WZl6cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MmjWNlE4QTZ4MkK=
SKMEL28 M{nETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vm[|AvPSEQvF2= Mon4NU82NzhiZB?= NVzxNHU4cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M2radFIyPzl4NkKy
MeWo MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:wMlUh|ryP NWDTbZo5OS93L{ig[C=> NFixdZdqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NHjKR5gzOTd7Nk[yNi=>
B16 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiwMlUh|ryP MknxNU82NzhiZB?= M1rZ[olvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MmT6NlE4QTZ4MkK=
Ly 1 NXL6W2tNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTyXYtVOjRiaB?= NFWwZXZKSzVyPUeuN{DPxE1? M2LEc|IyPzd{MES5
Ly 7 M2TLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPO[m8zPCCq NFS4SZBKSzVyPUGwMlch|ryP Mki0NlE4PzJyNEm=
Su-DHL6 NIq2S3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFux[5gzPCCq NU\OOXA5UUN3MP-8olIxKM7:TR?= M{jTflIyPzd{MES5
Ly 10 NXv5RpVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[1SFgzPCCq M3nZT2lEPTExvK6yNEDPxE1? MojZNlE4PzJyNEm=
RIVA M3;COmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLJNlQhcA>? NITjN3hKSzVy78{eNlAh|ryP Mn;aNlE4PzJyNEm=
Su-DHL2 NGWyTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2njdVI1KGh? NYO0NHlyUUN3MP-8olIxKM7:TR?= MUWyNVc4OjB2OR?=
Ly 1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH6OFghcA>? M3XZcmlEPTB;MD6zOEDPxE1? MmPJNlE4PzJyNEm=
Ly 7 MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj5V4o1QCCq NGjNUJRKSzVyPUCuNFI2KM7:TR?= M{CxTVIyPzd{MES5
Su-DHL6 M1PmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXS0PEBp MYrJR|Ux97zgMkCg{txO NHnNXWczOTd5MkC0PS=>
Ly 10 M3nZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy0PEBp NW\JfG5SUUN3ME2xMlgh|ryP NF;aWIwzOTd5MkC0PS=>
RIVA M{P4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYC0PEBp MojOTWM2OO,:nkKwJO69VQ>? M{fFUFIyPzd{MES5
Su-DHL2 M2fUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX70dGV4PDhiaB?= MXXJR|UxRTF5LkSg{txO NVrwVllmOjF5N{KwOFk>
Ly 1 NYrScIJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp NIPhNZhKSzVyPUCuNFEh|ryP Mlm3NlE4PzJyNEm=
Ly 7 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDK[HQ4OiCq M2\CNmlEPTB;MD6wNVgh|ryP Ml;FNlE4PzJyNEm=
Su-DHL6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\EeIc4OiCq M{LVUGlEPTB;MT62JO69VQ>? MYiyNVc4OjB2OR?=
Ly 10 NYHC[2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[3NkBp MVPJR|UxRTFwMjFOwG0> MnrLNlE4PzJyNEm=
RIVA NH3qTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\BO|IhcA>? MWTJR|Ux97zgMkCg{txO NXfRRmF5OjF5N{KwOFk>
Su-DHL2 M3raRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT4cHNSPzJiaB?= NXvIN2FsUUN3ME2xNU4zKM7:TR?= M1r3e|IyPzd{MES5

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID